Compare GPK & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | IDYA |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | 2007 | 2019 |
| Metric | GPK | IDYA |
|---|---|---|
| Price | $9.05 | $32.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $17.14 | ★ $51.21 |
| AVG Volume (30 Days) | ★ 6.3M | 727.5K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $8,617,000,000.00 | $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.98 | $191.08 |
| P/E Ratio | $6.33 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $9.15 | $13.45 |
| 52 Week High | $26.40 | $39.28 |
| Indicator | GPK | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 18.92 | 47.76 |
| Support Level | N/A | $32.85 |
| Resistance Level | $15.98 | $33.64 |
| Average True Range (ATR) | 0.43 | 1.23 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 1.02 | 25.93 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Paperboard Manufacturing, Americas Paperboard Packaging, and Europe Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company generates revenue from the Americas, Europe and Asia Pacific regions.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.